Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 8,839,063
  • Shares Outstanding, K 153,190
  • Annual Sales, $ 745,690 K
  • Annual Income, $ -208,440 K
  • 36-Month Beta 2.18
  • Price/Sales 11.90
  • Price/Cash Flow 0.00
  • Price/Book 7.30

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.64 +7.57%
on 04/27/17
60.79 -5.08%
on 05/05/17
+0.57 (+1.00%)
since 04/26/17
3-Month
52.54 +9.82%
on 02/27/17
62.50 -7.68%
on 03/02/17
+4.72 (+8.91%)
since 02/24/17
52-Week
39.65 +45.52%
on 06/27/16
62.50 -7.68%
on 03/02/17
+13.41 (+30.28%)
since 05/26/16

Most Recent Stories

More News
Shares of ALKS Up 57.5% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 14 months, Alkermes has returned 57.48% as of today's recent price of $58.77.

ALKS : 57.70 (-0.41%)
Alkermes to Present Data on ALKS 5461 at Upcoming Society of Biological Psychiatry Annual Meeting

Alkermes plc (NASDAQ: ALKS) today announced that data from FORWARD-5 and pooled data from FORWARD-4 and FORWARD-5, two phase 3 studies of ALKS 5461 for the adjunctive treatment of...

ALKS : 57.70 (-0.41%)
Uptrend Call Working As Alkermes Stock Rises 56.2% (ALKS)

SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 13 months, Alkermes has returned 56.24% as of today's recent price of $58.31.

ALKS : 57.70 (-0.41%)
Alkermes Rises 2.87% on Heavy Volume: Watch For Potential Pullback

Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $58.17 to a high of $60.24. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $59.09...

ALKS : 57.70 (-0.41%)
Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN clinical development program for...

ALKS : 57.70 (-0.41%)
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24...

HSKA : 97.40 (-0.58%)
GALE : 0.56 (-3.45%)
INFI : 1.72 (-1.15%)
ALKS : 57.70 (-0.41%)
Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 42nd Annual Health Care Conference

Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3, 2017 at...

ALKS : 57.70 (-0.41%)
DB : 18.46 (-2.07%)
Today's Top 10 Long/Short Estimize Signal Scores

Top 10 Positive Signal Scores Highlest likelihood of a positive pre/post earnings drift 1 STC Stewart Information Services Corporation Thu, Apr 20 ...

MTH : 40.35 (-0.37%)
STC : 44.85 (-0.29%)
CQP : 32.92 (-0.45%)
MIC : 78.37 (-0.04%)
NYLD : 18.35 (+1.66%)
KS : 21.05 (+1.01%)
CWST : 13.91 (+2.13%)
RVLT : 8.24 (-0.96%)
ALKS : 57.70 (-0.41%)
ASPN : 4.52 (+1.80%)
CCO : 3.60 (+1.41%)
NTNX : 19.59 (+11.50%)
LPX : 22.58 (-0.31%)
SBAC : 136.02 (+0.35%)
RGEN : 39.26 (+1.03%)
OIS : 29.15 (+1.57%)
CPE : 12.19 (+1.50%)
KRA : 33.39 (-1.10%)
SXC : 9.07 (+1.91%)
QDEL : 24.91 (-0.04%)
Alkermes Shares Up 52.0% Since SmarTrend's Buy Recommendation (ALKS)

SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on April 6th, 2016 at $37.32. In approximately 13 months, Alkermes has returned 52.01% as of today's recent price of $56.73.

ALKS : 57.70 (-0.41%)
Alkermes to Host Conference Call to Discuss First Quarter 2017 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, April 27, 2017, to discuss the company's first quarter 2017 financial results....

ALKS : 57.70 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Support & Resistance

2nd Resistance Point 59.05
1st Resistance Point 58.37
Last Price 57.70
1st Support Level 57.26
2nd Support Level 56.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.